Profund Advisors LLC Acquires 40,766 Shares of Dyne Therapeutics, Inc. $DYN

Profund Advisors LLC grew its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 88.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 86,746 shares of the company’s stock after buying an additional 40,766 shares during the quarter. Profund Advisors LLC’s holdings in Dyne Therapeutics were worth $1,697,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DYN. Chung Wu Investment Group LLC bought a new stake in Dyne Therapeutics during the third quarter worth approximately $30,000. Strs Ohio purchased a new stake in Dyne Therapeutics during the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $128,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

DYN has been the topic of several analyst reports. HC Wainwright cut their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 15th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Insider Activity at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 83,219 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total value of $1,512,921.42. Following the transaction, the director directly owned 7,962 shares in the company, valued at approximately $144,749.16. This represents a 91.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas Kerr sold 1,564 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $28,715.04. Following the completion of the transaction, the insider directly owned 170,042 shares in the company, valued at $3,121,971.12. This represents a 0.91% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,559,462 shares of company stock valued at $29,814,746 over the last ninety days. Company insiders own 14.14% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $17.56 on Thursday. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The firm has a market capitalization of $2.90 billion, a P/E ratio of -5.45 and a beta of 1.08. The stock has a 50 day moving average price of $18.38 and a 200 day moving average price of $18.44.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) earnings per share. As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.